Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Q32 Bio Inc. (QTTB)

$15.15 -1.50% NASDAQ: QTTB · 15-min delayed
  • WALTHAM, Massachusetts
  • Public · NASDAQ: QTTB
  • 22 employees
$222.3MMarket cap
$53.7MRevenue · FY2025
$29.8MNet income
22Employees
QTTBNASDAQ
2024IPO

About Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$53.7M
Net income
$29.8M
Total assets
$61.8M
Market cap
$222.3M
Operating margin
31.5%
Net margin
55.5%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$53.7M
Operating expenses
$36.8M
Operating income
$16.9M
Income tax
$0
Net income
$29.8M
EPS (basic)
$2.42
EPS (diluted)
$2.42

Balance sheet

Total assets
$61.8M
Current assets
$55.0M
Total liabilities
$19.8M
Current liabilities
$11.3M
Shareholders’ equity
$42.0M

Cash flow

Operating cash flow
-$33.5M
Investing cash flow
$7.0M
Financing cash flow
-$3.1M
Net cash flow
-$29.7M

Statements via Polygon.io (SEC filings)

NASDAQ: QTTB
$15.15 -1.50%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.36 $21.38

52-week range

Market cap
$222.3M
P/E ratio
6.3
EPS (diluted)
$2.42
Shares outstanding
14.7M
Open
Day range
Prev close
Volume
IPO date
Mar 26, 2024

Q32 Bio Inc. (QTTB) Stock Price

  • Profitable — net income of $29.8M in FY2025.
  • Trading 29% below its 52-week high.
  • Valued at a price-to-earnings (P/E) ratio of 6.3.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Q32 Bio Inc..

Write a review
Newsroom

News about Q32 Bio Inc.

News & sentiment via Polygon.io

FAQ

Q32 Bio Inc.: frequently asked questions

Is Q32 Bio Inc. an American company?

Q32 Bio Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Q32 Bio Inc. headquartered?

Q32 Bio Inc. is headquartered in Waltham, Massachusetts, United States.

Is Q32 Bio Inc. publicly traded?

Yes — Q32 Bio Inc. is a publicly traded company. Its stock trades under the ticker symbol QTTB on the NASDAQ.

What does Q32 Bio Inc. do?

Q32 Bio Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →